

OHMR Research Ethics and Governance Metrics Program



Metrics Activity Report for NSW PHOs

Reporting Period: Quarter 2 2023
01/04/2023 – 30/06/2023

NSW Office for Health and Medical Research



Executive Summary

This report includes strategic and site level performance and compliance metrics that are collected by the Office for Health and Medical Research (OHMR) from NSW Public Health Organisations (PHOs) on studies authorised during the reporting period. The performance of NSW PHOs on health and medical research are reported four times a year, each covering a 3-month period.

Overall Performance Environment

REGIS is the online platform used to manage ethics and governance applications for all NSW Public Health Organisations. OHMR has undertaken data validation activities with LHD Research Office staff to accurately represent research ethics and governance performance on this platform. These rolling validation activities may result in data reported here to differ from previous reports.

Update to Metrics Program

As reported previously, OHMR implemented the following changes to the Research Key Performance Indicators (KPIs) for inclusion in the Chief Executives' Services Agreement:

- Change benchmark to/measure/Total Time/rather than time spent with LHD Research Office alone
- Number of Greater than Low Risk projects (GLR) processed within application total time
 - 90 days for ethics, 60 days for governance
 - Threshold changes
 - >75% = Performing
 - 55%-75% = Underperforming
 - <55% = Not performing



Ethics Review Timelines of Human Research in NSW PHOs

KPI21-03: Ethics Application Approvals - By the Human Research Ethics Committee (HREC) within 90 calendar days

NSW State Benchmark: The benchmark for the 2021/22 financial year onwards is for reviewing human research studies by NSW PHO HRECs within 90 calendar days

Definition:

The proportion of Ethics applications (excluding LNR) approved by the HREC within 90 calendar days, approved within the reporting period.

Context:

The measure will no longer account for clock stops in accordance with the NHMRC Certification Handbook. Instead, the end-to-end time will be measured. Where a valid application is received, the clock starts on the submission closing date for the HREC meeting at which an application will be reviewed. The clock is stopped when the HREC formally notifies the applicant of the final decision.

Desired Outcome:

Ensuring timely processing of ethics approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.

Selection Criteria Summary:

Scope	Human Research Ethics Applications
Frequency	Quarterly
Inclusions	<ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = Approved/ Approved with conditions within the reporting period
Exclusions	<ul style="list-style-type: none"> Application Type = Low and negligible risk Approval Type = Not within the reporting period Migrated studies

Total

Total time is defined as the measurement of the total, unadjusted time from the Submission Closing Date of the first meeting the application is assigned to, to when the final decision notification email is sent.

Summary for Metric 3

Ethics review performance of NSW HRECs according to the < **90-day benchmark** for studies approved during the reporting period (**Quarter 2 2023**) are shown in **Table 1**.

During the reporting period, 245 studies (greater than low risk pathway) were approved by a NSW Health HREC with an average review time (total time) of 52 days. Of these 245 studies, 88 (36%) were classified as clinical trials (**Table 2**).

Further breakdown of clinical trial approvals by sponsor type is provided in **Table 3** (by NSW PHOs) and **Table 4** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications is presented in **Table 5**.

Table 1. The **90 calendar days benchmark** for approval of human research ethics applications (**greater than low risk**) during the reporting period.

Ethics Approval (Q2 2023)						
All greater than low risk applications						
NSW PHOs	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	21	20	95%	48	26	22
CINSW	8	6	75%	77	50	28
HNELHD	29	29	100%	31	17	14
ISLHD	3	3	100%	67	39	27
JHFMHN	4	4	100%	46	43	3
NBMLHD	3	3	100%	76	42	35
NNSWLHD	2	1	50%	86	54	32
NSLHD	31	27	87%	52	33	20
SCHN	12	12	100%	59	32	27
SESLHD	13	13	100%	64	49	15
SLHD-CCD	7	7	100%	57	24	32
SLHD-RPA	53	53	100%	37	20	18
SVHN	13	11	85%	65	28	37
SWSLHD	14	12	86%	57	38	19
WNSWLHD	5	5	100%	39	26	12
WSLHD	27	20	74%	75	49	26
TOTAL	245	226	92%	52	31	21

Table 2. The 90 calendar days benchmark for the approval of clinical trials (greater than low risk) during the reporting period.

Ethics Approval (Q2 2023)						
Clinical Trials						
NSW PHOs	Total Number of Applications	Total Time 90 Day Benchmark			Total Time Breakdown (calendar days)	
		Count < 90 Day Benchmark	% < 90 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Researcher Time
BLLBRRY	21	20	95%	48	26	22
CINSW	0	0	-	-	-	-
HNELHD	6	6	100%	35	16	19
ISLHD	0	0	-	-	-	-
NSLHD	9	5	56%	97	58	39
SCHN	6	6	100%	69	36	34
SESLHD	2	2	100%	53	47	7
SLHD-CCD	2	2	100%	61	25	36
SLHD-RPA	17	17	100%	46	23	24
SVHN	7	6	86%	57	27	30
SWSLHD	6	6	100%	52	35	17
WNSWLHD	0	0	-	-	-	-
WSLHD	12	9	75%	72	49	23
TOTAL	88	79	90%	58	33	25

Table 3. Breakdown of NSW PHO performances in **clinical trial approvals** (greater than low risk) during the reporting period **by sponsor type**

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
BLLBRRY	1	35	173	19	26	41	1	28	49
CINSW	0	-	-	0	-	-	0	-	-
HNELHD	0	-	-	0	-	-	6	16	35
ISLHD	0	-	-	0	-	-	0	-	-
NSLHD	2	42	86	3	61	98	4	65	102
SCHN	0	-	-	4	34	61	2	39	85
SESLHD	2	47	53	0	-	-	0	-	-
SLHD-CCD	0	-	-	2	25	61	0	-	-
SLHD-RPA	4	26	54	4	26	55	9	20	40
SVHN	0	-	-	5	29	60	2	24	51
SWSLHD	0	-	-	4	38	52	2	30	51
WNSWLHD	0	-	-	0	-	-	0	-	-
WSLHD	1	51	53	5	51	78	6	47	71
Grand Total	10	37	72	46	33	56	32	32	57

Table 4. Quarterly **clinical trial approvals** (greater than low risk) in the last 3 reporting period (between 01/10/2022 and 30/06/2023), **by sponsor type**

	Q4 2022			Q1 2023			Q2 2023		
Sponsor Type	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
Collaborative Group	9	28	50	11	39	89	10	37	72
Commercial Entity	29	34	67	45	42	58	46	33	56
Investigator Initiated	28	30	69	23	31	69	32	32	57
Total	66	32	65	79	37	65	88	33	58

Table 5. Historical performance of NSW PHOs against the old and new benchmarks for the review and approval of human research ethics applications (greater than low risk) in the last 3 reporting period (between 01/10/2022 and 30/06/2023).

NSW PHOs	Q4 2022							Q1 2022							Q2 2023						
	Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)			Total Number of Applications	45 Day Benchmark (with clock)			90 Day Benchmark (without clock)		
		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)		Count 45 Day Benchmark	% 45 Day Benchmark	Average Research Office Time (Days)	Count 90 Day Benchmark	% 90 Day Total Time Benchmark	Average Total Time (Days)
BLLBRRY	15	11	73%	46	11	73%	73	23	20	87%	19	22	96%	44	21	20	95%	22	20	95%	48
CINSW	9	9	100%	10	9	100%	42	3	3	100%	21	2	67%	66	8	6	75%	28	6	75%	77
HNELHD	29	29	100%	14	29	100%	31	32	30	94%	22	32	100%	37	29	29	100%	14	29	100%	31
ISLHD	2	2	100%	15	2	100%	50	0	0	-	-	0	-	-	3	3	100%	27	3	100%	67
JHFMHN	4	3	75%	54	3	75%	100	3	3	100%	38	3	100%	73	4	4	100%	3	4	100%	46
NBMLHD	8	8	100%	19	8	100%	54	4	4	100%	20	4	100%	71	3	2	67%	35	3	100%	76
NNSWLHD	1	1	100%	6	1	100%	37	3	2	67%	32	2	67%	53	2	2	100%	32	1	50%	86
NSLHD	8	6	75%	47	6	75%	91	14	9	64%	54	4	29%	122	31	27	87%	20	27	87%	52
SCHN	13	11	85%	20	12	92%	43	11	9	82%	25	10	91%	62	12	11	92%	27	12	100%	59
SESLHD	21	21	100%	15	20	95%	59	22	19	86%	26	20	91%	70	13	13	100%	15	13	100%	64
SLHD-CCD	8	3	38%	45	8	100%	66	5	3	60%	44	5	100%	63	7	5	71%	32	7	100%	57
SLHD-RPA	40	38	95%	23	40	100%	43	33	24	73%	33	32	97%	53	53	53	100%	18	53	100%	37
SVHN	27	21	78%	51	21	78%	83	28	21	75%	41	21	75%	78	13	8	62%	37	11	85%	65
SWSLHD	20	18	90%	23	20	100%	50	20	18	90%	20	17	85%	54	14	13	93%	19	12	86%	57
WNSWLHD	5	5	100%	15	4	80%	44	4	2	50%	214	2	50%	272	5	5	100%	12	5	100%	39
WSLHD	17	16	94%	22	14	82%	70	20	16	80%	25	20	100%	64	27	21	78%	26	20	74%	75
TOTAL	227	202	89%	27	208	92%	56	225	183	81%	32	196	87%	65	245	222	91%	21	226	92%	52



Site-specific Assessment (SSA) Authorisation Timelines of Human Research Projects in NSW PHOs

KPI21-04: Research Governance Application Authorisations – SSA Authorisations within 60 calendar days									
<p>NSW State Benchmark: The benchmark for the 2021/22 financial year onwards for authorisation of SSA applications is 60 calendar days</p>									
<p>Definition: The proportion of site-specific assessment (SSA) applications (excluding lower to negligible risk) authorised by the Research Governance Office (RGO) within 60 calendar days, authorised within the reporting period.</p> <p>Context: The measure will no longer account for clock stops in accordance with the National Health and Medical Research Council Certification. Handbook. Instead, the end-to-end time will be measured. The SSA application received date is the date the RGO or designee receives an SSA application from a researcher regardless of whether it is complete and/or deemed valid. The clock is stopped when the final SSA decision letter is provided to the site principal investigator.</p> <p>Desired Outcome: Ensuring timely processing of site approvals for research and clinical trials supports better health outcomes for the people of NSW and maintaining competitiveness through access to the latest treatments from clinical trials.</p>	<p>Selection Criteria Summary:</p> <table border="1"> <tr> <td>Scope</td> <td>Site-specific assessment (SSA) applications</td> </tr> <tr> <td>Frequency</td> <td>Quarterly</td> </tr> <tr> <td>Inclusions</td> <td> <ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = “Authorised” or “authorised with conditions” within the reporting period </td> </tr> <tr> <td>Exclusions</td> <td> <ul style="list-style-type: none"> Application Type = Low and negligible risk Migrated studies </td> </tr> </table> <p>Total Time: Total time is the measurement of the total, unadjusted time from the Submission Date to when the final decision notification email is sent granting approval.</p>	Scope	Site-specific assessment (SSA) applications	Frequency	Quarterly	Inclusions	<ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = “Authorised” or “authorised with conditions” within the reporting period 	Exclusions	<ul style="list-style-type: none"> Application Type = Low and negligible risk Migrated studies
Scope	Site-specific assessment (SSA) applications								
Frequency	Quarterly								
Inclusions	<ul style="list-style-type: none"> Study Type = All Application Type = Greater than low risk Approval Type = “Authorised” or “authorised with conditions” within the reporting period 								
Exclusions	<ul style="list-style-type: none"> Application Type = Low and negligible risk Migrated studies 								

Summary:

SSA review performance of NSW PHOs according to the **<60-day benchmark** for studies authorised during the reporting period (**Quarter 1 2023**) are shown in **Table 6**. During the reporting period, **433** studies (greater than low risk pathway) were authorised in NSW PHOs with an average review time (total time) of **40** days. Of these **433** studies, **221** were classified as clinical trials (**Table 7**). Further breakdown of clinical trial SSA authorisations by sponsor type is provided in **Table 8** (by NSW PHOs) and **Table 9** (by quarter). Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of governance applications is presented in **Table 10**.

Table 6: The 60 calendar days benchmark for authorisation of governance applications (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q2 2023)							
	All greater than low risk applications							
		60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
	Total Number of Applications	Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
Calvary	14	13	93%	18	6	5	1	7
CCLHD	14	14	100%	12	5	4	0	3
FWLHD	0	0	-	-	-	-	-	-
HNELHD	35	34	97%	25	10	6	1	9
ISLHD	18	18	100%	7	1	5	0	2
JHFMHN	2	2	100%	29	29	1	0	0
MLHD	1	0	0%	80	7	2	1	71
MNCLHD	12	10	83%	42	10	6	2	27
NBMLHD	7	7	100%	46	20	12	4	15
NNSWLHD	4	3	75%	33	5	26	2	2
NSLHD	29	25	86%	40	11	6	1	23
NSWHPTH	7	1	14%	124	19	37	0	68
SCHN	25	25	100%	38	10	9	0	19
SESLHD	41	35	85%	42	8	11	0	22
SLHD-CCD	20	20	100%	29	3	4	5	22
SLHD-RPA	50	50	100%	22	2	11	2	9
SNSWLHD	1	0	0%	119	77	41	0	1
SVHN	39	28	72%	66	10	18	0	38
SWSLHD	43	39	91%	62	30	11	0	20
WNSWLHD	5	4	80%	22	2	11	0	10
WSLHD	66	56	85%	48	9	13	3	26
TOTAL	433	384	89%	40	10	11	1	20

Table 7: The 60 calendar days benchmark for the authorisation of clinical trials (greater than low risk) during the reporting period.

NSW PHOs	SSA Approvals (Q2 2023) Clinical Trials							
	Total Number of Applications	60 Day Benchmark (without clock)			Total Time Breakdown (calendar days)			
		Count of < 60 Day Benchmark	% < 60 Day Total Time Benchmark	Average Total Time (Days)	Average Research Office Time	Average Head of Dept Time	Average Chief Exec Time	Average Researcher Time
ASNSW	0	0	-	-	-	-	-	-
CALVARY	10	9	90%	20	7	4	1	9
CCLHD	9	9	100%	16	5	7	0	4
FWLHD	0	0	-	-	-	-	-	-
HNELHD	12	11	92%	33	10	11	1	12
ISLHD	9	9	100%	8	1	3	0	3
JHFMHN	0	0	-	-	-	-	-	-
MLHD	0	0	-	-	-	-	-	-
MNCLHD	5	4	80%	43	15	3	2	26
NBMLHD	4	4	100%	51	21	15	5	15
NNSWLHD	2	2	100%	7	2	5	0	0
NSLHD	13	11	85%	43	15	6	1	21
NSWHPTH	3	0	0	134	18	35	0	81
SCHN	15	15	100%	42	11	11	0	21
SESLHD	21	19	90%	43	7	17	0	19
SLHD-CCD	11	11	100%	27	3	2	7	23
SLHD-RPA	21	21	100%	34	1	19	1	14
SNSWLHD	1	0	0%	119	77	41	0	1
SVHN	20	17	85%	53	11	18	0	24
SWSLHD	19	16	84%	77	29	15	0	33
WNSWLHD	1	1	100%	8	1	7	0	0
WSLHD	45	38	84%	43	8	14	2	21
TOTAL	221	197	89%	42	10	13	1	19

Table 8. NSW PHO performances in clinical trial authorisations (greater than low risk) during the reporting period, by sponsor type.

NSW PHOs	Collaborative group			Commercial entity			Investigator-initiated		
	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)	Total # of Applications	Average Research Office Time (days)	Average Total Time (days)
ASNSW	0	-	-	0	-	-	0	-	-
CALVARY	3	10	46	4	7	9	3	4	8
CCLHD	4	7	17	3	5	11	2	3	24
FWLHD	0	-	-	0	-	-	0	-	-
HNELHD	2	17	44	1	7	26	9	9	31
ISLHD	1	1	8	5	2	9	3	1	5
JHFMHN	0	-	-	0	-	-	0	-	-
MLHD	0	-	-	0	-	-	0	-	-
MNCLHD	1	36	160	3	8	12	1	12	21
NBMLHD	2	29	57	2	12	45	0	-	-
NNSWLHD	1	4	8	1	0	5	0	-	-
NSLHD	2	8	107	9	19	32	2	6	29
NSWHPTH	0	-	-	0	-	-	0	-	-
SCHN	3	9	45	9	10	41	3	12	42
SESLHD	3	6	31	15	7	35	3	9	92
SLHD-CCD	2	12	50	9	1	23	0	-	-
SLHD-RPA	4	1	29	13	0	34	4	2	36
SNSWLHD	0	-	-	0	-	-	1	77	119
SVHN	1	5	16	14	10	31	5	15	121
SWSLHD	5	30	119	7	26	42	7	30	81
WNSWLHD	0	-	-	1	1	8	0	-	-
WSLHD	7	9	65	22	5	21	16	13	64
Total	41	12	56	118	8	28	62	13	60

Table 9. Quarterly clinical trial authorisations (greater than low risk applications) approved during the last 3 reporting period, by sponsor type

	Q4 2022			Q1 2022			Q2 2023		
Sponsor Type	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time	Total # of Applications	Average Research Office	Average Total Time
Collaborative Group	49	7	43	38	11	42	41	12	56
Commercial Entity	118	10	37	94	9	26	118	8	28
Investigator Initiated	70	8	48	70	14	51	62	13	60
Total	237	9	42	202	11	38	221	10	42

Table 10. Historical performance of NSW PHOs against the old and new benchmarks for the review and authorisation of SSA applications (greater than low risk) for the last 3 reporting periods (between 01/10/2022 and 30/06/2023).

LHD	Q4 2022						Q1 2023						Q2 2023								
	Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (without clock)			60 Day Benchmark (without clock)			Number of Applications	15 Day Benchmark (with clock)			60 Day Benchmark (without clock)		
		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)		Count of 15 Day Benchmark	% 15 Day Benchmark	Average RO Time (Days)	Count of 60 Day Benchmark	% 60 Day Total Time Benchmark	Average Total Time (Days)
ASNSW	0	0	-	-	0	-	-	1	0	0	26	1	100%	29	0	0	-	-	0	-	-
CALVARY	10	9	90%	5	10	100%	10	11	9	82%	13	10	91%	20	14	13	93%	6	13	93%	18
CCLHD	7	7	100%	4	7	100%	27	10	10	100%	3	10	100%	19	14	13	93%	5	14	100%	12
FWLHD	2	1	50%	13	1	50%	80	0	0	-	-	0	-	-	0	0	-	-	0	-	-
HNELHD	32	29	91%	9	31	97%	27	43	27	63%	12	42	98%	31	35	25	71%	10	34	97%	25
ISLHD	19	19	100%	2	18	95%	11	13	13	100%	2	13	100%	9	18	18	100%	1	18	100%	7
JHFMHN	2	1	50%	30	2	100%	33	2	0	0	22	2	100%	26	2	0	0	29	2	100%	29
MLHD	5	4	80%	11	5	100%	28	3	3	100%	6	3	100%	7	1	1	100%	7	0	0%	80
MNCLHD	5	5	100%	6	5	100%	30	6	4	67%	15	6	100%	34	12	10	83%	10	10	83%	42
NBMLHD	15	8	53%	24	12	80%	54	23	10	43%	16	23	100%	35	7	3	43%	20	7	100%	46
NNSWLHD	7	5	71%	9	7	100%	17	2	1	50%	16	2	100%	22	4	3	75%	5	3	75%	33
NSLHD	35	11	31%	28	25	71%	57	27	14	52%	15	21	78%	47	29	20	69%	11	25	86%	40
NSWHPH	9	4	44%	15	7	78%	57	11	6	55%	15	5	45%	69	7	3	43%	19	1	14%	124
SCHN	36	31	86%	8	26	72%	76	32	28	88%	8	21	66%	57	25	22	88%	10	25	100%	38
SESLHD	47	38	81%	9	41	87%	35	53	45	85%	10	40	75%	40	41	33	80%	8	35	85%	42
SLHD-CCD	22	22	100%	2	22	100%	24	26	25	96%	3	26	100%	23	20	19	95%	3	20	100%	29
SLHD-RPA	70	60	86%	6	63	90%	27	57	51	89%	5	57	100%	20	50	49	98%	2	50	100%	22
SNSWLHD	0	0	-	-	0	-	-	2	0	0%	77	0	0%	84	1	0	0%	77	0	0%	119
SVHN	29	24	83%	9	18	62%	55	20	19	95%	7	17	85%	37	39	34	87%	10	28	72%	66
SWSLHD	61	60	98%	6	46	75%	66	50	34	68%	12	39	78%	51	43	1	2%	30	39	91%	62
WNSWLHD	11	9	82%	6	11	100%	16	6	5	83%	7	5	83%	33	5	5	100%	2	4	80%	22
WSLHD	64	63	98%	6	57	89%	29	40	36	90%	9	33	83%	40	66	55	83%	9	56	85%	48
Total	488	410	84%	9	414	85%	40	438	340	78%	10	376	86%	37	433	327	76%	10	384	89%	40

A list of NSW PHOs names and abbreviations that review and/or authorise human research studies:

Human Research Ethics Committee/ Research Governance Office Names	Abbreviation used in the tables	Ethics	Site
Ambulance Service of NSW	ASNSW		Yes
Bellberry	BLLBRRY	Yes	
Calvary Mater Hospital Newcastle	CALVARY		Yes
Central Coast LHD	CCLHD		Yes
NSW Population & Health Services Research Ethics Committee	CINSW	Yes	
Greater Western LHD	WNSWLHD	Yes	Yes
Hammond Care	HCARE		Yes
Hunter New England LHD	HNELHD	Yes	Yes
Justice Health & Forensic Mental Health Network	JHFMHN	Yes	Yes
Mid North Coast LHD	MNCLHD		Yes
Murrumbidgee LHD	MLHD		Yes
Northern NSW LHD	NNSWLHD	Yes	Yes
Nepean Blue Mountains LHD	NBMLHD	Yes	Yes
Northern Sydney LHD	NSLHD	Yes	Yes
NSW Health Pathology	NSWHPTH		Yes
Royal Rehabilitation Centre Sydney HREC	RRCS	Yes	
Sydney Children's Hospitals Network	SCHN	Yes	Yes
South Eastern Sydney LHD	SESLHD	Yes	Yes
Sydney LHD (Concord Zone)	SLHD – CCD	Yes	Yes
Sydney LHD (RPAH Zone)	SLHD – RPA	Yes	Yes
Southern NSW LHD	SNSWLHD		Yes
St Vincent's Hospital	SVHN	Yes	Yes
South Western Sydney LHD	SWSLHD	Yes	Yes
Illawarra Shoalhaven LHD (joint committee with University of Wollongong)	ISLHD	Yes	Yes
Western Sydney LHD	WSLHD	Yes	Yes



For more information

This report has been prepared by the Research Ethics and Governance Unit in Office for Health and Medical Research.

For further enquiries and for the use of this report please contact:

James Cokayne

Principal Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9920](tel:(02)93919920) | james.cokayne@health.nsw.gov.au

Yagiz Alp Aksoy

Senior Policy Officer

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9461 7887](tel:(02)94617887) | yagiz.aksoy@health.nsw.gov.au

Jackie Nie

Policy Officer and Data Analyst

Research Ethics and Governance Unit

Office for Health and Medical Research

[Tel \(02\) 9391 9854](tel:(02)93919854) | Jackie.nie@health.nsw.gov.au